HRP20100147T1 - Inhibitori proteina akt (protein kinaza b) - Google Patents
Inhibitori proteina akt (protein kinaza b) Download PDFInfo
- Publication number
- HRP20100147T1 HRP20100147T1 HR20100147T HRP20100147T HRP20100147T1 HR P20100147 T1 HRP20100147 T1 HR P20100147T1 HR 20100147 T HR20100147 T HR 20100147T HR P20100147 T HRP20100147 T HR P20100147T HR P20100147 T1 HRP20100147 T1 HR P20100147T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- compound
- treatment
- glioblastoma
- pharmaceutical preparation
- Prior art date
Links
- 108091008611 Protein Kinase B Proteins 0.000 title 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 4
- RECFXYRAGCPZOS-UHFFFAOYSA-N 4-[5-(2-aminoethylsulfonyl)isoquinolin-7-yl]phenol Chemical compound C=1C2=CN=CC=C2C(S(=O)(=O)CCN)=CC=1C1=CC=C(O)C=C1 RECFXYRAGCPZOS-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000005017 glioblastoma Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 210000000481 breast Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000001672 ovary Anatomy 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- WRBAEXPHVMKWSP-UHFFFAOYSA-N 4-[5-(2-aminoethylsulfonyl)isoquinolin-7-yl]phenol;hydrochloride Chemical group Cl.C=1C2=CN=CC=C2C(S(=O)(=O)CCN)=CC=1C1=CC=C(O)C=C1 WRBAEXPHVMKWSP-UHFFFAOYSA-N 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 206010029096 Neoplasm prostate Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000004877 mucosa Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 201000005404 rubella Diseases 0.000 claims 2
- 208000000649 small cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- LWEAAWDKHBZPDJ-UHFFFAOYSA-N 4-[5-(2-aminoethylsulfonyl)isoquinolin-7-yl]phenol;dihydrochloride Chemical group Cl.Cl.C=1C2=CN=CC=C2C(S(=O)(=O)CCN)=CC=1C1=CC=C(O)C=C1 LWEAAWDKHBZPDJ-UHFFFAOYSA-N 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80526006P | 2006-06-20 | 2006-06-20 | |
| US88576507P | 2007-01-19 | 2007-01-19 | |
| PCT/US2007/070945 WO2007149730A2 (en) | 2006-06-20 | 2007-06-12 | Inhibitors of akt (protein kinase b) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100147T1 true HRP20100147T1 (hr) | 2010-04-30 |
Family
ID=38834248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100147T HRP20100147T1 (hr) | 2006-06-20 | 2010-03-15 | Inhibitori proteina akt (protein kinaza b) |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7998977B2 (ja) |
| EP (1) | EP2035385B1 (ja) |
| JP (1) | JP2009541335A (ja) |
| KR (1) | KR101067551B1 (ja) |
| AR (1) | AR061240A1 (ja) |
| AT (1) | ATE455102T1 (ja) |
| AU (1) | AU2007261120A1 (ja) |
| BR (1) | BRPI0713136A2 (ja) |
| CA (1) | CA2652612A1 (ja) |
| CL (1) | CL2007001752A1 (ja) |
| DE (1) | DE602007004333D1 (ja) |
| DK (1) | DK2035385T3 (ja) |
| DO (1) | DOP2008000053A (ja) |
| EA (1) | EA015712B1 (ja) |
| EC (1) | ECSP088992A (ja) |
| ES (1) | ES2336630T3 (ja) |
| HR (1) | HRP20100147T1 (ja) |
| IL (1) | IL195005A0 (ja) |
| MA (1) | MA30757B1 (ja) |
| MX (1) | MX2008015904A (ja) |
| NO (1) | NO20090289L (ja) |
| PE (1) | PE20080338A1 (ja) |
| PL (1) | PL2035385T3 (ja) |
| PT (1) | PT2035385E (ja) |
| SI (1) | SI2035385T1 (ja) |
| TN (1) | TNSN08529A1 (ja) |
| TW (1) | TW200812970A (ja) |
| WO (1) | WO2007149730A2 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8217047B2 (en) | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
| EP2613786A4 (en) | 2010-09-07 | 2013-10-23 | Dmi Acquisition Corp | TREATMENT OF DISEASES |
| JP2014530063A (ja) | 2011-10-10 | 2014-11-17 | アンピオ ファーマシューティカルズ，インコーポレイテッド | 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法 |
| PL2766029T3 (pl) | 2011-10-10 | 2020-08-24 | Ampio Pharmaceuticals, Inc. | Leczenie choroby zwyrodnieniowej stawów |
| KR20140095479A (ko) | 2011-10-28 | 2014-08-01 | 앰피오 파마슈티컬스 인코퍼레이티드 | 비염의 치료 |
| US9808454B2 (en) | 2013-03-15 | 2017-11-07 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| AU2015305611B2 (en) | 2014-08-18 | 2020-04-23 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| US10123997B2 (en) * | 2015-06-15 | 2018-11-13 | Yong Liao | Target for treating hepatitis B virus |
| US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN115843298B (zh) * | 2020-07-22 | 2024-03-29 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| CA2518180A1 (en) | 2003-03-28 | 2004-11-04 | Eli Lilly And Company | Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b) |
| GB0317315D0 (en) | 2003-07-24 | 2003-08-27 | Astex Technology Ltd | Pharmaceutical compounds |
| WO2005054202A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
-
2007
- 2007-06-06 AR ARP070102429A patent/AR061240A1/es unknown
- 2007-06-12 KR KR1020087030916A patent/KR101067551B1/ko not_active IP Right Cessation
- 2007-06-12 AU AU2007261120A patent/AU2007261120A1/en not_active Abandoned
- 2007-06-12 PL PL07798410T patent/PL2035385T3/pl unknown
- 2007-06-12 SI SI200730212T patent/SI2035385T1/sl unknown
- 2007-06-12 ES ES07798410T patent/ES2336630T3/es active Active
- 2007-06-12 US US12/300,358 patent/US7998977B2/en not_active Expired - Fee Related
- 2007-06-12 DE DE602007004333T patent/DE602007004333D1/de active Active
- 2007-06-12 BR BRPI0713136-4A patent/BRPI0713136A2/pt not_active IP Right Cessation
- 2007-06-12 PT PT07798410T patent/PT2035385E/pt unknown
- 2007-06-12 JP JP2009516633A patent/JP2009541335A/ja not_active Ceased
- 2007-06-12 AT AT07798410T patent/ATE455102T1/de active
- 2007-06-12 EA EA200970041A patent/EA015712B1/ru not_active IP Right Cessation
- 2007-06-12 WO PCT/US2007/070945 patent/WO2007149730A2/en active Application Filing
- 2007-06-12 CA CA002652612A patent/CA2652612A1/en not_active Abandoned
- 2007-06-12 EP EP07798410A patent/EP2035385B1/en active Active
- 2007-06-12 DK DK07798410.2T patent/DK2035385T3/da active
- 2007-06-12 MX MX2008015904A patent/MX2008015904A/es active IP Right Grant
- 2007-06-15 CL CL2007001752A patent/CL2007001752A1/es unknown
- 2007-06-18 PE PE2007000768A patent/PE20080338A1/es not_active Application Discontinuation
- 2007-06-20 TW TW096122142A patent/TW200812970A/zh unknown
-
2008
- 2008-10-24 DO DO2008000053A patent/DOP2008000053A/es unknown
- 2008-10-30 IL IL195005A patent/IL195005A0/en unknown
- 2008-12-18 EC EC2008008992A patent/ECSP088992A/es unknown
- 2008-12-19 TN TNP2008000529A patent/TNSN08529A1/en unknown
-
2009
- 2009-01-19 NO NO20090289A patent/NO20090289L/no not_active Application Discontinuation
- 2009-01-19 MA MA31573A patent/MA30757B1/fr unknown
-
2010
- 2010-03-15 HR HR20100147T patent/HRP20100147T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602007004333D1 (de) | 2010-03-04 |
| DK2035385T3 (da) | 2010-03-22 |
| US20090221633A1 (en) | 2009-09-03 |
| JP2009541335A (ja) | 2009-11-26 |
| ECSP088992A (es) | 2009-01-30 |
| AR061240A1 (es) | 2008-08-13 |
| PE20080338A1 (es) | 2008-04-25 |
| EA015712B1 (ru) | 2011-10-31 |
| IL195005A0 (en) | 2009-08-03 |
| BRPI0713136A2 (pt) | 2012-04-17 |
| CL2007001752A1 (es) | 2008-01-18 |
| AU2007261120A1 (en) | 2007-12-27 |
| WO2007149730A2 (en) | 2007-12-27 |
| EP2035385A2 (en) | 2009-03-18 |
| MX2008015904A (es) | 2009-01-12 |
| EA200970041A1 (ru) | 2009-06-30 |
| WO2007149730A3 (en) | 2008-04-24 |
| KR101067551B1 (ko) | 2011-09-27 |
| US7998977B2 (en) | 2011-08-16 |
| NO20090289L (no) | 2009-01-19 |
| CA2652612A1 (en) | 2007-12-27 |
| TNSN08529A1 (en) | 2010-04-14 |
| TW200812970A (en) | 2008-03-16 |
| EP2035385B1 (en) | 2010-01-13 |
| DOP2008000053A (es) | 2009-01-15 |
| PL2035385T3 (pl) | 2010-06-30 |
| ES2336630T3 (es) | 2010-04-14 |
| ATE455102T1 (de) | 2010-01-15 |
| KR20090015978A (ko) | 2009-02-12 |
| MA30757B1 (fr) | 2009-10-01 |
| SI2035385T1 (sl) | 2010-05-31 |
| PT2035385E (pt) | 2010-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100147T1 (hr) | Inhibitori proteina akt (protein kinaza b) | |
| EA038122B9 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| CN104507481B (zh) | 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物 | |
| HRP20180746T4 (hr) | Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze | |
| TN2018000219A1 (en) | Soluble guanylate cyclase stimulators | |
| WO2014209841A3 (en) | Compounds for treating spinal muscular atrophy | |
| WO2007042786A3 (en) | 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors | |
| RS50600B (sr) | Kristalni oblik gama - d ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže | |
| SI3057959T1 (en) | DNA-PK INHIBITORS | |
| MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. | |
| UA115320C2 (uk) | Інгібітори кінази | |
| SG11201901894TA (en) | Anti-influenza virus pyrimidine derivatives | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| MX2009011579A (es) | Pirimidinonas como moduladores de caseina cinasa ii (ck2). | |
| EA201291348A1 (ru) | Активаторы растворимой гуанилатциклазы | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| EA200800502A1 (ru) | Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения | |
| AR087672A1 (es) | Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer | |
| PH12014501278A1 (en) | Kinase inhibitors | |
| MX2019013815A (es) | Inhibidor de antigenos de superficie del virus de la hepatitis b. | |
| EA201792071A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| HRP20110244T1 (hr) | Postupak liječenja raka | |
| PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof |